Alzheimer's Disease

Questions discussed in this category

How does APOE4 status affect your clinical decision-making in patients who may be eligible for anti-amyloid therapies for early Alzheimer's disease?

Does APOE4 status have any impact on how you would choose between lecanemab vs donanemab?

5 Answers available

How do you counsel eligible patients on how to decide between lecanemab vs donanemab?

3 Answers available

What is the minimum level of cognitive symptoms that would prompt you to pursue biomarker testing required for anti-amyloid therapies for Alzheimer's?

4 Answers available

What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?

3 Answers available

What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?

2 Answers available

What are the best practices for centers interested in providing anti-amyloid therapies for early Alzheimer's to ensure treatment delivery success?

2 Answers available

Would you administer IV thrombolysis in a patient presenting with disabling stroke symptoms while on anti-amyloid therapy?

4 Answers available

How will your approach to screening and diagnosis of early dementia change given newly available therapies for early Alzheimer's disease?

5 Answers available

How do you explain the clinical benefit of lecanemab or donanemab to patients?

Do you feel the study outcomes are clinically meaningful?

3 Answers available

Is there a point at which further reduction in amyloid burden is no longer clinically meaningful or should the goal always be as much reduction as possible?

4 Answers available

How will you counsel patients regarding ARIA?

Do you see utility in trending serum neurofilament light chain levels or any alternative screening methods beyond MRI to help identify amyloid-related...

2 Answers available

What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

Are there patients in whom you would specifically avoid this class of treatments?

2 Answers available

Papers discussed in this category

JAMA, 2023 Jul 17

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022 Aug 15

The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.

The journal of prevention of Alzheimer's disease, 2022

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.

The New England journal of medicine, 2023 Jan 04

Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.

The journal of prevention of Alzheimer's disease, 2023

Lecanemab: Appropriate Use Recommendations.

Related Topics